In contrast, Zhang et al. [16] observed no associations between ARID1A loss and clinical stage, depth of myometrial invasion, lymph node metastasis, or OS among endometrial carcinoma patients. Here, ARID1A is linked to metastatic malignant neoplasm in the lymph nodes.